ArticleFrontiers in immunology2021
A Validation Study Comparing Risk Prediction Models of IgA Nephropathy.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Systematic review of the application of the Kidney Failure Risk Equation and Oxford classification in estimating prognosis in IgA Nephropathy.Systematic reviews · 2025Pooled it
- Representation of multimorbidity and frailty in the development and validation of kidney failure prognostic prediction models: a systematic review.BMC medicine · 2024Pooled it
- Segmental Glomerulosclerosis Subclassification in the Oxford Classification System (MEST-C) Improves the International IgA Nephropathy Prediction Tool.Journal of clinical medicine · 2026Article
- Timing of treatment-switch to telitacicept in high-risk IgA nephropathy: an observational case series of two clinical scenarios.BMC nephrology · 2026Observational
- Prognostic Stratification in Primary Glomerulonephritis: Integrating Histology, Biomarkers, and Risk Prediction Models.Life (Basel, Switzerland) · 2026Review
- Novel therapies improve prognosis of IgAN and limit the applicability of the International IgA Nephropathy Prediction Tool.Clinical kidney journal · 2025Article
- Efficacy and safety of telitacicept in IgA nephropathy: real-world study outcomes.Clinical kidney journal · 2025Article
- [Clinicopathological significance and prognostic value of serum 25-hydroxyvitamin DZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Article
- Machine learning-based diagnosis and prognosis of IgAN: A systematic review and meta-analysis.Heliyon · 2024Review
- External Validation of the Kidney Failure Risk Equation Among Urban Community-Based Chinese Patients With CKD.Kidney medicine · 2024Article
- Sequential administration of paricalcitol followed by IL-17 blockade for progressive refractory IgA nephropathy patients.Scientific reports · 2024Article
- External validation of the pediatric International IgA Nephropathy Prediction Tool in a central China cohort.Clinical and experimental nephrology · 2024Article
- Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis.Clinical kidney journal · 2023Review
- Evaluating Progression Risk in Patients With Immunoglobulin A Nephropathy.Kidney international reports · 2023Review
- Urinary N-Acetyl-Beta-D-Glucosaminidase levels predict immunoglobulin a nephropathy remission status.BMC nephrology · 2023Article
- Validation of two IgA nephropathy risk-prediction tools using a cohort with a long follow-up.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Article
- External validation of the international prediction tool in Korean patients with immunoglobulin A nephropathy.Kidney research and clinical practice · 2022Article
- Finerenone in Primary IgA Nephropathy: A Matched Case-Control Study.Kidney diseases (Basel, Switzerland)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to validate three IgAN risk models proposed by an international collaborative study and another CKD risk model generated by an extended CKD cohort with our multicenter Chinese IgAN cohort. Biopsy-proven IgAN patients with an eGFR ≥15 ml/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.